Marker Therapeutics Announced Non-clinical Data Of Its Lead Multi-Tumor-Associated Antigen (multiTAA)-Specific T Cell Product Candidate, MT-401, In An Off-The-Shelf Setting And Provided An Update On Clinical Readiness For The Off-The-Shelf Program
Benzinga Newsdesk - Aug 7, 2023, 7:36AM